GlaxoSmithKline PLC on Tuesday said the US Food & Drug Administration has accepted the company’s application for the review of kidney disease drug daprodustat.

The Brentford, England-based pharmaceutical company described the FDA review acceptance as a third major milestone after winning regulatory submission acceptance by the European Medicines Agency and the approval of Duvroq, the same drug under a different name, in Japan.

Daprodustat is used on patients for the treatment of anaemia of chronic kidney disease.

GlaxoSmithKline shares were 0.6% lower at 1,762.60 pence each in London on Tuesday morning.

Copyright 2022 Alliance News Limited. All Rights Reserved.